Oruka Therapeutics closes 9.66M-share offering at $72.50; prelim cash $496M

Oruka Therapeutics, Inc.

Oruka completed underwritten public offering of 9,660,000 shares of common stock at $72.50 per share, raising gross proceeds of approximately $700 million.
Underwriters have a 30-day option to purchase up to an additional 1,449,000 shares at the public offering price.
Preliminary estimate of cash, cash equivalents, and investments as of March 31, 2026 is approximately $496 million.
Offering closed April 30, 2026; underwriting agreement dated April 28, 2026 with Leerink, TD, Goldman Sachs, Stifel, Guggenheim.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.